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Summary
Patients with chronic kidney disease have 
risk factors for cardiovascular disease which 
are additional to those found in the general 
population. many patients will die of cardiovascular 
disease before they require dialysis for their kidney 
disease. While lifestyle modification is essential, 
it is important to manage the patient's anaemia, 
dyslipidaemia and hypertension. managing heart 
failure can be difficult because of the need to 
adjust the patient's fluid balance according to renal 
and cardiac function. If the progression of chronic 
kidney disease can be slowed, cardiac risk may be 
reduced.
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Introduction
Chronic kidney disease, defined by a glomerular filtration rate 
(GFR) under 60 mL/min/1.73 m2 or evidence of kidney damage 
(for example, proteinuria) for at least three months, is a major 
public health problem. At least one in seven Australian adults 
has at least one marker of kidney damage or dysfunction.1 
Chronic kidney disease is one of the most potent risk factors 
for cardiovascular disease. Patients with advanced chronic 
kidney disease have up to a 10- to 20-fold greater risk of cardiac 
death than age- and sex-matched controls.2 These patients are 
up to 20 times more likely to die from cardiovascular disease 
than to survive to require dialysis.3 However, patients with 
chronic kidney disease who also have cardiovascular disease 
are more likely to progress to renal failure than those without 
cardiovascular disease.4 
The 'traditional' risk factors, listed in Table 1, are independent 
predictors of cardiovascular disease in chronic kidney disease, 
but do not account for the total increased risk. There are also 
many 'non-traditional' cardiovascular risk factors which play 
a potentially important role in chronic kidney disease. There is 
randomised controlled trial evidence that timely intervention 
can substantially reduce the progression of renal failure, and 
can reduce cardiovascular risk by up to 50%.5
modifying cardiovascular risk in patients with 
chronic kidney disease
As chronic kidney disease accelerates cardiovascular disease, 
management of the risk factors should begin as soon as 
possible. 
Lifestyle modification
Lifestyle modification underpins all other therapeutic 
approaches and must continue to be practised throughout the 
treatment of chronic kidney disease.6 Particular attention should 
be paid to smoking, nutrition, alcohol and physical activity 
(Table 2).7 Successful modification of the patient's lifestyle can 
reduce blood pressure.
All guidelines recommend a reduction of dietary sodium for 
patients with hypertension and chronic kidney disease. A 
meta-analysis of 20 randomised trials involving patients with 
hypertension found that halving salt intake (from approximately 
10 g per day to 5 g per day) for four or more weeks had a modest 
but important effect on lowering blood pressure (–5.06 mmHg 
(95% CI* –5.81 to –4.31) for systolic and –2.70 mmHg (95% CI 
–3.16 to –2.24) for diastolic blood pressure).8 In addition to direct 
*  CI  confidence interval
Table 1
'Traditional' and 'non-traditional' cardiovascular risk 
factors in chronic kidney disease 2
Traditional risk factors Non-traditional risk factors
Older age
Male
Hypertension
Dyslipidaemia (high LDL    
  and low HDL cholesterol)
Diabetes
Smoking
Physical inactivity
Family history of  
  (premature onset)  
  cardiovascular disease
Left ventricular hypertrophy 
Albuminuria
Elevated homocysteine
Elevated lipoprotein (a)
Anaemia
Abnormal calcium and  
  phosphate metabolism
Extracellular fluid volume  
  overload
Oxidative stress
Inflammation (C-reactive  
  protein)
Malnutrition
Thrombogenic factors
LDL low density lipoprotein
HDL high density lipoprotein
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effects on blood pressure, lowering the extracellular volume by 
limiting sodium intake significantly enhances the response to 
most antihypertensive drugs, especially angiotensin converting 
enzyme (ACE) inhibitors and angiotensin receptor antagonists.
The consensus on dietary protein intake in Australia for people 
with chronic kidney disease is to advise a normal intake 
(0.75–1.0 g/kg body weight/day).5 Reduced protein intake is 
of inconsistent benefit and may accentuate the chance of 
malnutrition.
Hypertension
In patients with chronic kidney disease, hypertension is the most 
powerful risk factor for the progression of kidney dysfunction 
and the development of cardiovascular disease. The most 
important goal for reducing cardiovascular risk in patients with 
chronic kidney disease is to lower blood pressure to a target  
(<130/80 mmHg if proteinuria less than 1 g/day or <125/75 mmHg 
if proteinuria more than 1 g/day).5,6 In order to reach these 
targets, multiple (often 3–4) antihypertensive drugs are often 
needed, particularly in more advanced chronic kidney disease.5 
The activity of the renin-angiotensin-aldosterone system 
is increased so ACE inhibitors are the first-line therapy for 
patients with chronic kidney disease, although angiotensin 
receptor antagonists may provide comparable renoprotection 
(preservation of renal function) and therefore cardioprotection. 
The degree of renoprotection appears to be greater in patients 
with more severe kidney failure and in those who experience a 
greater initial increase in serum creatinine concentration when 
treatment begins.5 It is therefore important not to withdraw ACE 
inhibitors or angiotensin receptor antagonists in patients with 
chronic kidney disease who experience an acute rise in plasma 
creatinine concentration of less than 30% which stabilises within 
the first two months of treatment. These individuals are the 
ones who are most likely to derive the greatest renoprotective 
benefit.5,6 However, if the rise in creatinine is more than 
30% above the baseline value, stop the drugs and consider 
investigating the possibility of bilateral renal artery stenosis.6 
ACE inhibitors and angiotensin receptor antagonists should also 
be withdrawn if the serum potassium concentration exceeds  
6 mmol/L, despite dose reduction, dietary potassium restriction 
and concomitant diuretic therapy. However, the frequency of 
this complication in patients with chronic kidney disease is less 
than 2%, with the average rise in serum potassium being of the 
order of 0.5 mmol/L.
Other antihypertensive drugs have a role, as optimal blood 
pressure control often requires combination therapy. Diuretics, 
beta blockers and calcium channel blockers are commonly used. 
When a diuretic is given to treat hypertension or oedema in a 
patient with chronic kidney disease, a loop diuretic is generally 
preferred, because thiazide diuretics become less effective as 
monotherapy when the GFR falls below 50 mL/min/1.73 m2.6 
However, thiazides still produce additive effects when  
co-administered with a loop diuretic.
Dyslipidaemia
Chronic kidney disease is associated with hyperlipidaemia.  
A meta-analysis of 50 randomised trials involving over  
30 000 patients found that statin use significantly reduced fatal 
cardiovascular events by 19% and non-fatal cardiovascular 
events by 22%, irrespective of the stage of chronic kidney 
disease.9 Although there have been concerns about an 
increased incidence of rhabdomyolysis with statins in chronic 
kidney disease, their adverse effect profile in this large 
group of patients was similar to that of placebo. Current 
guidelines therefore recommend that statins be used to reduce 
cardiovascular risk in patients with chronic kidney disease. Aim 
for a serum total cholesterol below 4 mmol/L and a low density 
lipoprotein cholesterol below 2.5 mmol/L.
Glycaemic control in patients with  
diabetes mellitus
Diabetes is a common cause of renal failure. Intensive blood 
glucose control significantly reduces the risk of developing 
chronic kidney disease and reduces cardiovascular risk. Current 
guidelines recommend aiming for a glycated haemoglobin 
(HbA1c) of less than 7%. 
Metformin is the first-line drug and can be used in patients with 
chronic kidney disease with a GFR above 60 mL/min/1.73 m2. 
In patients with a GFR of 30–60 mL/min/1.73 m2, the maximum 
recommended dose should be halved. Avoid metformin if the 
GFR is under 30 mL/min/1.73 m2. All patients should be warned 
Table 2 
Treatment targets for patients with chronic kidney disease 15
Parameter Target
Smoking Cease smoking
Weight BMI 18–25 kg/m2
Waist circumference ≤94 cm (male), 
≤80 cm (female) 
Nutrition Dietary salt intake 40–100 mmol/day
Alcohol <2 standard glasses alcohol/day 
(men)
<1 standard glass alcohol/day 
(women)
Physical activity >30 mins physical activity/day
Blood pressure <130/80 mmHg
<125/75 mmHg if proteinuria >1 g/day
Proteinuria >50% reduction of baseline value
Cholesterol Total <4.0 mmol/L
LDL <2.5 mmol/L
Blood glucose (for 
people with diabetes)
Pre-prandial blood glucose  
4.4–6.7 mmol/L
HbA1c <7.0%
BMI body mass index
LDL low density lipoprotein
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to cease metformin for up to a few days during intercurrent 
illness or around the time of receiving radiographic contrast 
media. Dose reduction is often required for oral hypoglycaemic 
drugs (and insulin) as kidney function declines. 
Caution should be exercised with thiazolidinediones in chronic 
kidney disease, particularly as there is the possibility of 
significant fluid retention. 
Anaemia
Anaemia is a common complication of chronic kidney disease 
and is associated with the development of left ventricular 
hypertrophy and increased cardiovascular risk. This complication 
starts when the GFR is below 60 mL/min/1.73 m2 and its 
prevalence increases with decreasing GFR. Treatment of  
anaemia in chronic kidney disease can be accomplished with 
iron supplementation and erythropoiesis stimulating drugs  
(such as epoietin alfa, epoietin beta, darbepoietin alfa). 
Erythropoiesis stimulating drugs have substantial health 
benefits for patients with chronic kidney disease, including 
improved quality of life, reduced blood transfusion requirements, 
decreased left ventricular mass, diminished sleep disturbance 
and enhanced exercise capacity. The vast majority of patients 
treated with erythropoiesis stimulating drugs require 
concomitant iron supplementation, either as oral iron or as a 
periodic intravenous dose.
There is currently no evidence that normalising haemoglobin 
concentrations in patients with chronic kidney disease improves 
clinical outcomes. Two large randomised controlled trials and a 
meta-analysis10 have shown increased morbidity and mortality 
with higher haemoglobin targets. Current practice guidelines 
therefore recommend a haemoglobin target of 11–12 g/dL for all 
patients with chronic kidney disease. 
Calcium and phosphate metabolism
Hyperphosphataemia and hyperparathyroidism in chronic 
kidney disease have been associated with increased vascular 
calcification, cardiovascular risk and death. This often manifests 
when the GFR falls below 60 mL/min/1.73 m2. It becomes more 
prevalent as kidney function declines and is present in most 
patients having dialysis. Although there is no definitive evidence 
yet that correcting calcium-phosphate balance or secondary 
hyperparathyroidism improves cardiovascular outcomes, 
current clinical practice guidelines recommend treatment. This 
includes varying combinations of dietary phosphate restriction 
(preferably with the assistance of a renal dietitian), phosphate 
binder administration with meals (e.g. calcium carbonate, 
aluminium hydroxide, sevelamer, lanthanum carbonate, 
magnesium trisilicate), vitamin D supplementation (calcitriol 
or a vitamin D analogue such as paricalcitol) or calcimimetic 
therapy (cinacalcet). Recommended targets for treatment 
include a serum phosphate below 1.65 mmol/L, a serum calcium 
within the normal range and serum parathyroid hormone 
approximately 2–3 times the upper reference limit.
Aspirin and other treatments
Low-dose aspirin should be considered in patients with 
chronic kidney disease, especially in those with established 
cardiovascular disease. The only published controlled trial in 
patients with chronic kidney disease found that aspirin reduced 
the risk of myocardial infarction, but did not reduce the overall 
risk of cardiovascular death.11 The potential benefit must be 
weighed against the risk of gastrointestinal bleeding, which is 
increased in patients with chronic kidney disease.
There is currently no convincing evidence to recommend 
routine prescription of folic acid, antioxidants (such as vitamin E 
or N-acetylcysteine) or fibrates to reduce cardiovascular risk in 
chronic kidney disease. 
managing cardiovascular disease in chronic 
kidney disease
Those with chronic kidney disease are more likely to be 
hospitalised for cardiovascular disease than those without.12 
Controlling the progression of renal disease may help to limit 
these complications.
Cardiac failure
Cardiac and renal failure often coexist because dysfunction of 
one organ frequently causes dysfunction of the other or because 
common systemic diseases, such as diabetes mellitus and 
extensive atherosclerosis, often cause both cardiac and renal 
dysfunction. Cardiac failure is present in up to 40% of patients 
with chronic kidney disease.12 Hospitalisations for cardiac failure 
are five times more common in patients with chronic kidney 
disease than in other patients. The incidence is further increased 
by 30% in patients having dialysis.12 Cardiac failure in renal 
disease should be managed as usual. 
Diuretics are frequently required for symptomatic management 
and to control fluid retention in chronic kidney disease. The 
combined effects of renal failure (impaired delivery to site 
of action) and cardiac failure (impaired response) mean that 
patients with cardiorenal failure require frequent administration 
of large doses of loop diuretics (e.g. frusemide 120 mg twice 
a day) to achieve an adequate diuretic response.7 This attempt 
to remove fluid must be balanced against the need to avoid 
dehydration and further deterioration of kidney function. Clinical 
signs of excessive fluid removal include postural hypotension 
(postural drop in systolic blood pressure of more than 10 mmHg) 
and postural tachycardia (postural rise in pulse rate of more 
than 10 beats/min). Daily weighing and fluid balance records 
may assist with optimisation of fluid balance.
Blockade of the renin-angiotensin-aldosterone system (ACE 
inhibitors and angiotensin receptor antagonists) and beta 
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blockade (bisoprolol, carvedilol or long-acting metoprolol) 
improves prognosis. ACE inhibitors and angiotensin receptor 
antagonists are underused in patients who have heart failure 
with chronic kidney disease, possibly due to fears about the 
effects on renal function.13 However, prescription of these drugs 
is associated with a significant reduction in deaths (adjusted 
one-year mortality) in these patients.13 Adding the angiotensin 
receptor antagonist telmisartan to an ACE inhibitor in a 
randomised controlled trial in 303 haemodialysis patients with 
symptomatic heart failure significantly reduced both  
all-cause mortality (20% risk reduction) and hospitalisations 
due to congestive heart failure. If patients cannot tolerate ACE 
inhibitor or angiotensin receptor antagonist therapy, consider 
giving them a combination of hydralazine and nitrate therapy  
to improve their prognosis. 
Carvedilol significantly improved all-cause mortality (49% 
risk reduction), cardiovascular death (68% risk reduction) and 
hospitalisations (56% risk reduction) in a randomised, placebo-
controlled trial of 114 patients with heart failure having dialysis.14 
Spironolactone and eplerenone should not be given to patients 
with a creatinine clearance of less than 30 mL/min/1.73 m2. 
Caution should still be exercised when giving these drugs to 
patients with milder degrees of renal impairment, especially 
if they are taking an ACE inhibitor or angiotensin receptor 
antagonist. There is a significant potential for hyperkalaemia, as 
well as deterioration in renal function. 
Ischaemic heart disease
Ischaemic heart disease is very common in patients with chronic 
kidney disease. It progresses at a more rapid rate than in people 
without chronic kidney disease and is often undertreated.12 
A study of patients with ischaemic heart disease and chronic 
kidney disease managed in primary health care showed that 
their risk factors for coronary heart disease were not as well 
controlled as those of patients with normal GFR.15 Even though 
patients with chronic kidney disease had a higher prevalence of 
diabetes mellitus and hypertension, the rate of prescription of 
evidence-based cardiovascular therapies (aspirin, beta blockers, 
ACE inhibitors, statins) was lower than for those with normal 
renal function. This situation is undesirable, but may be caused 
in part by the perception of a higher number of complications, 
fear of adverse effects, and less evidence from controlled trials 
in this population.
Current recommendations are that patients with chronic kidney 
disease with ischaemic heart disease should be prescribed 
aspirin, beta blockers, ACE inhibitors and statins to achieve 
similar targets to those currently suggested for patients without 
chronic kidney disease. International best practice clinical 
guidelines also recommend that percutaneous coronary 
intervention and coronary artery bypass grafting are appropriate 
revascularisation techniques for patients with chronic kidney 
disease who have obstructive lesions in their coronary arteries.
When angiography is to be performed, some strategies to 
decrease the risk of contrast nephropathy might include:
n	 minimising contrast load
n	 temporary cessation of drugs such as ACE inhibitors, 
angiotensin receptor antagonists, diuretics (if practical) and 
metformin around the time of contrast exposure (typically for 
24–48 hours before and 24–48 hours after the procedure)
n	 gentle pre-hydration, for example 1 L of saline infused over 
12 hours before the procedure.
Conclusion
Chronic kidney disease is a common, under-recognised 
and eminently treatable condition that affects one in seven 
Australians. It is also a major risk factor for cardiovascular 
disease. Patients with chronic kidney disease are far more 
likely to die of ischaemic heart disease or congestive cardiac 
failure than to end up on dialysis. Cardiovascular risk factor 
modification is an important part of the management of 
chronic kidney disease. There is considerable overlap between 
the management of chronic kidney disease, diabetes and 
cardiovascular risk reduction. Additional risk factor reduction 
strategies in patients with chronic kidney disease include 
treatment of anaemia and calcium and phosphate disorders. 
Management of cardiac failure and ischaemic heart disease in 
patients with chronic kidney disease is not dissimilar to that 
in patients without chronic kidney disease, except that more 
intensive diuresis is often necessary in cardiorenal failure.
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Self-test questions
The following statements are either true or false  
(answers on page 167)
5. Treating hypertension can reduce the decline of the 
glomerular filtration rate in patients with chronic kidney 
disease.
6. Diuretics are contraindicated for the treatment of heart 
failure in patients with chronic kidney disease.
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Catherine Liu, Academic General Practice 
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This book provides recommendations for assessment and 
management of common clinical problems as well as expert 
advice on 'evidence-poor' areas. A notable difference from the 
previous Cardiovascular edition is the inclusion of an opening 
chapter explaining how the guidelines were produced, including 
the role of the expert group and the process of formulating and 
revising the recommendations. This explanation is important for 
the reader's understanding of the basis of the guidelines and 
represents a useful addition to the text. 
Book review
Other differences between the revised version and its 
predecessor are the absence of the cardiovascular drug 
interactions chapter and the management of cerebral arterial 
disease (it still discusses peripheral arterial disease), and the 
logical transfer of the section on treatment of endocarditis to 
Therapeutic Guidelines: Antibiotics. This edition also has a focus 
on cardiovascular disease risk reduction as well as including the 
updated indications for statin therapy that are consistent with 
current Pharmaceutical Benefits Schedule guidelines.
The layout of this edition is familiar and navigable. However, 
overall I have found using the electronic form of  Therapeutic 
Guidelines (eTG) easier to use in general practice as the search 
function is very user-friendly and information from the entire 
series can be accessed without needing to refer to individual 
books.  
